IS8410A - Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma - Google Patents

Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma

Info

Publication number: IS8410A
Authority: IS; Iceland
Prior art keywords: reagents; treatment; methods; inflammatory disorders; immune inflammatory
Prior art date: 2003-09-15

Application number

IS8410A

Other languages

English (en)

Inventor

Roydon Jost-Price Edward

B. Brasher Bradley

W. Chappell Todd

Manivasakam Palaniyandi

Sachs Noah

Smith Brendan

A. Auspitz Benjamin

S. Slavonic Michael

Original Assignee

Combinatorx, Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-15

Filing date

2006-04-12

Publication date

2006-04-12

2006-04-12 Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated

2006-04-12 Publication of IS8410A publication Critical patent/IS8410A/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Neurology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS8410A 2003-09-15 2006-04-12 Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma IS8410A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50302603P	2003-09-15	2003-09-15
PCT/US2004/030210 WO2005027839A2 (en)	2003-09-15	2004-09-15	Methods and reagents for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number	Publication Date
IS8410A true IS8410A (is)	2006-04-12

Family

ID=34375301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8410A IS8410A (is)	2003-09-15	2006-04-12	Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma

Country Status (18)

Country	Link
US (1)	US20050192261A1 (is)
EP (1)	EP1670427A4 (is)
JP (1)	JP2007516217A (is)
KR (1)	KR20060089725A (is)
CN (1)	CN101102760A (is)
AR (1)	AR047841A1 (is)
AU (1)	AU2004273880A1 (is)
BR (1)	BRPI0414435A (is)
CA (1)	CA2537989A1 (is)
IL (1)	IL174185A0 (is)
IS (1)	IS8410A (is)
MX (1)	MXPA06002929A (is)
NO (1)	NO20061239L (is)
RU (1)	RU2006112587A (is)
SG (1)	SG146653A1 (is)
TW (1)	TW200522932A (is)
WO (1)	WO2005027839A2 (is)
ZA (1)	ZA200601973B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6765001B2 (en) *	2001-12-21	2004-07-20	Medicis Pharmaceutical Corporation	Compositions and methods for enhancing corticosteroid delivery
GB2389530B (en) *	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
US7704527B2 (en) *	2002-10-25	2010-04-27	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
CA2514061A1 (en) *	2003-02-14	2004-09-02	Combinatorx, Incorporated	Combination therapy for the treatment of immunoinflammatory disorders
AU2004292445B2 (en) *	2003-11-21	2010-02-04	Zalicus Inc.	Methods and reagents for the treatment of inflammatory disorders
US8758816B2 (en)	2004-11-24	2014-06-24	Meda Pharmaceuticals Inc.	Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en)	2004-11-24	2007-01-25	Medpointe Healthcare Inc.	Compositions comprising azelastine and methods of use thereof
ES2704482T3 (es)	2004-11-24	2019-03-18	Meda Pharmaceuticals Inc	Composiciones que comprenden azelastina y sus métodos de uso
BRPI0518829A2 (pt)	2004-12-06	2008-12-09	Avigen Inc	mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
SI1719507T1 (sl)	2005-04-13	2010-11-30	Astion Dev As	Beta adrenoceptor agonisti za zdravljenje bolezni veznega tkiva kože
DK1874821T3 (da)	2005-04-26	2013-07-08	Trion Pharma Gmbh	Kombination af antistoffer med glykokortikoider til behandling af kræft
US20090324699A1 (en) *	2005-09-01	2009-12-31	Lena Preswetoff-Morath	Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders
RU2008122978A (ru) *	2005-11-09	2009-12-20	Комбинаторкс, Инкорпорейтед (Us)	Способы, композиции и наборы для лечения медицинских состояний
US20070179121A1 (en) *	2006-02-02	2007-08-02	Plott R T	Method of treating pediatric patients with corticosteroids
RU2008139625A (ru) *	2006-03-07	2010-04-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Композиции и способы лечения ревматоидного артрита
JP5352452B2 (ja) *	2006-06-06	2013-11-27	メディシノバ，インコーポレイテッド	置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
US9205080B2 (en) *	2006-11-16	2015-12-08	Transderm, Inc.	Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
GB0701171D0 (en) *	2007-01-22	2007-02-28	Imp Innovations Ltd	Compositions and uses thereof
WO2008127975A2 (en) *	2007-04-11	2008-10-23	Alcon Research, Ltd.	Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US7536799B2 (en) *	2007-06-07	2009-05-26	Keson Industries	Chalk line apparatus with strategically located chalk fill opening
US9149463B2 (en) *	2007-09-18	2015-10-06	The Board Of Trustees Of The Leland Standford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) *	2007-09-18	2015-08-11	The Board Of Trustees Of The Leland Stanford Junior University	Methods and composition of treating a flaviviridae family viral infection
US8940730B2 (en)	2007-09-18	2015-01-27	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions of treating a Flaviviridae family viral infection
US9061010B2 (en) *	2007-09-18	2015-06-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection
WO2010021681A2 (en) *	2008-08-18	2010-02-25	Combinatorx (Singapore) Pte. Ltd.	Compositions and methods for treatment of viral diseases
WO2010048264A2 (en) *	2008-10-23	2010-04-29	Combinatorx, Incorporated	Methods and compositions for the treatment of immunoinflammatory disorders
US8975247B2 (en) *	2009-03-18	2015-03-10	The Board Of Trustees Of The Leland Stanford Junion University	Methods and compositions of treating a flaviviridae family viral infection
EA016240B1 (ru) *	2009-10-13	2012-03-30	Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи"	Способ прогнозирования эффективности лечения больных псориазом инфликсимабом
GB201121812D0 (en)	2011-12-07	2012-02-01	Teva Branded Pharmaceutical Prod R & D Inc	NAsal formulation
EP2705847B1 (en) *	2012-09-05	2014-07-02	PSoriasis+Creams Sweden AB	Composition for treating psoriasis
CN103830731A (zh) *	2012-11-26	2014-06-04	天津金耀集团有限公司	糖皮质激素与h1受体拮抗剂的复方吸入组合物
CN103830728A (zh) *	2012-11-26	2014-06-04	天津金耀集团有限公司	环索奈德与h1受体拮抗剂的复方吸入药物
CN103830208A (zh) *	2012-11-26	2014-06-04	天津金耀集团有限公司	含有h1受体拮抗剂的吸入制剂
CN103830730A (zh) *	2012-11-26	2014-06-04	天津金耀集团有限公司	布地奈德与h1受体拮抗剂的复方吸入药物
BR102012030828A2 (pt)	2012-12-03	2014-09-16	Ems Sa	Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
US9370527B2 (en)	2012-12-28	2016-06-21	The Regents Of The University Of Michigan	Amelioration of intestinal fibrosis and treatment of Crohn's disease
WO2014117035A1 (en)	2013-01-24	2014-07-31	Transderm, Inc.	COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6769970B2 (ja) *	2015-01-12	2020-10-14	エージェンシーフォーサイエンス，テクノロジーアンドリサーチ	免疫媒介性疾患の防止及び処置におけるムラミルペプチドに対するモノクローナル抗体
CN104940179B (zh) *	2015-05-29	2017-10-27	中国人民解放军第二军医大学	盐酸苯海拉明在制备治疗实验性自身免疫性脑脊髓炎药物中的应用
IL300476B2 (en) *	2015-06-30	2024-07-01	Eiger Group Int Inc	Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
RU2627424C1 (ru) *	2016-11-03	2017-08-08	Лонг Шенг Фарма Лимитед	Фармацевтический препарат для лечения ревматологических заболеваний
IL302385B2 (en)	2017-01-06	2024-06-01	Palvella Therapeutics Inc	Non-aqueous preparations of mTOR inhibitors and methods of use
WO2019178516A1 (en) *	2018-03-16	2019-09-19	SEN-JAM Pharmaceutical LLC	Methods and compositions to treat enteropathic arthritis
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
AU2021372255A1 (en) *	2020-10-30	2023-06-15	The Board Of Trustees Of The Leland Stanford Junior University	Drugs targeting inflammation for the treatment of osteoarthritis and other inflammatory diseases
CN118903128B (zh) *	2024-08-07	2025-03-25	中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所)	阿司咪唑在制备治疗Tfh相关自身免疫性疾病药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3231468A (en) *	1962-07-02	1966-01-25	Merck & Co Inc	Dexamethasone-cyproheptadine oral antiflammatory compositions
US3419655A (en) *	1967-03-17	1968-12-31	American Home Prod	Treatment of inflammations by administering a cycloleucyl compound
US4444780A (en) *	1982-08-30	1984-04-24	Ortho Pharmaceutical Corporation	Method for treating atopic dermatitis
US5166149A (en) *	1989-09-08	1992-11-24	Chemex Pharmaceuticals, Inc.	Methotrexate compositions and methods of treatment using same
US5030634A (en) *	1990-03-29	1991-07-09	Krumdieck Carlos L	10-deazaaminopterin: a new arthritis remittive drug
US6096737A (en) *	1994-10-05	2000-08-01	Loder; Cari	Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
AU4472396A (en) *	1994-12-30	1996-07-24	American Home Products Corporation	Clear non-alcoholic hydrocortisone solutions
US5736537A (en) *	1995-09-12	1998-04-07	Estee Lauder, Inc.	Dehydroep:androsterone sailcylate useful against skin atrophy
EP0780127A1 (en) *	1995-12-19	1997-06-25	The Procter & Gamble Company	A nasal spray containing a steroid and a antihistamine
AU3153797A (en) *	1996-06-04	1998-01-05	Procter & Gamble Company, The	A nasal spray containing an intranasal steroid and an antihistamine
IN188720B (is) *	1997-11-06	2002-11-02	Panacea Biotec Ltd
US6140337A (en) *	1997-12-23	2000-10-31	Schering Corporation	Methods for the treatment of mental disorders
US6423721B1 (en) *	1998-09-10	2002-07-23	Schering Corporation	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
AU3126700A (en) *	1998-12-18	2000-07-03	Du Pont Pharmaceuticals Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1049471A1 (en) *	1999-03-01	2000-11-08	Schering Corporation	Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
GB0023220D0 (en) *	2000-09-21	2000-11-01	Arakis Ltd	Corticosteroid formulation
US20020006961A1 (en) *	1999-05-14	2002-01-17	Katz Stanley E.	Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2284531T3 (es) *	1999-10-08	2007-11-16	Schering Corporation	Tratamiento nasal topico usando desloratadina y furoato de mometasona.
AU2001255268A1 (en) *	2000-04-07	2001-10-23	Schering Corporation	Inhibition of cytokine generation
US6488937B1 (en) *	2000-08-23	2002-12-03	William Smits	Allergy treatment method using a rapid immunotherapy protocol
CA2424555A1 (en) *	2000-10-02	2002-04-11	Emory University	Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6599914B2 (en) *	2001-04-24	2003-07-29	Schering Corporation	Inhibition of cytokine generation
US7034059B2 (en) *	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
WO2003020274A1 (en) *	2001-08-30	2003-03-13	Aventis Pharmaceuticals Inc.	Treatment of atopic dermatitis
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2514061A1 (en) *	2003-02-14	2004-09-02	Combinatorx, Incorporated	Combination therapy for the treatment of immunoinflammatory disorders

2004
- 2004-09-14 TW TW093127736A patent/TW200522932A/zh unknown
- 2004-09-14 US US10/940,902 patent/US20050192261A1/en not_active Abandoned
- 2004-09-15 BR BRPI0414435-0A patent/BRPI0414435A/pt not_active IP Right Cessation
- 2004-09-15 EP EP04784162A patent/EP1670427A4/en not_active Withdrawn
- 2004-09-15 SG SG200806907-2A patent/SG146653A1/en unknown
- 2004-09-15 AU AU2004273880A patent/AU2004273880A1/en not_active Abandoned
- 2004-09-15 WO PCT/US2004/030210 patent/WO2005027839A2/en not_active Ceased
- 2004-09-15 AR ARP040103302A patent/AR047841A1/es unknown
- 2004-09-15 JP JP2006526998A patent/JP2007516217A/ja active Pending
- 2004-09-15 MX MXPA06002929A patent/MXPA06002929A/es unknown
- 2004-09-15 CA CA002537989A patent/CA2537989A1/en not_active Abandoned
- 2004-09-15 CN CNA2004800336483A patent/CN101102760A/zh active Pending
- 2004-09-15 KR KR1020067006026A patent/KR20060089725A/ko not_active Withdrawn
- 2004-09-15 RU RU2006112587/15A patent/RU2006112587A/ru not_active Application Discontinuation
- 2004-09-15 ZA ZA200601973A patent/ZA200601973B/xx unknown
2006
- 2006-03-08 IL IL174185A patent/IL174185A0/en unknown
- 2006-03-17 NO NO20061239A patent/NO20061239L/no not_active Application Discontinuation
- 2006-04-12 IS IS8410A patent/IS8410A/is unknown

Also Published As

Publication number	Publication date
JP2007516217A (ja)	2007-06-21
EP1670427A4 (en)	2009-01-07
KR20060089725A (ko)	2006-08-09
NO20061239L (no)	2006-06-08
CA2537989A1 (en)	2005-03-31
EP1670427A2 (en)	2006-06-21
WO2005027839A3 (en)	2007-06-28
ZA200601973B (en)	2008-08-27
SG146653A1 (en)	2008-10-30
AU2004273880A1 (en)	2005-03-31
BRPI0414435A (pt)	2006-11-14
IL174185A0 (en)	2006-08-01
CN101102760A (zh)	2008-01-09
MXPA06002929A (es)	2006-06-14
AR047841A1 (es)	2006-03-01
RU2006112587A (ru)	2007-10-27
TW200522932A (en)	2005-07-16
US20050192261A1 (en)	2005-09-01
WO2005027839A2 (en)	2005-03-31

Publication	Publication Date	Title
IS8451A (is)	2006-05-11	Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is)	2006-04-12	Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20032220D0 (no)	2003-05-15	Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK1663978T3 (da)	2008-04-07	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
IS7977A (is)	2005-08-12	Samsetningar og aðferð til samsettra meðferðar
NO20053678D0 (no)	2005-07-29	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
DK3246399T3 (da)	2021-10-04	Alfavirus-partikler og fremgangsmåder til fremstilling
DK1888033T3 (da)	2014-05-26	Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
NO20040640L (no)	2004-08-16	Anordning og fremgangsmate
DK1824475T3 (da)	2011-06-06	Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK2308507T3 (da)	2015-04-20	Fremgangsmåder til behandling af præeklampsi
NO20053771D0 (no)	2005-08-08	Ringromsfluider og fremgangsmater for plassering av de samme
DK1620551T3 (da)	2014-01-13	Phospholipase og fremgangsmåde til fremstilling deraf
IS7202A (is)	2004-03-31	Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
IL179227A0 (en)	2007-03-08	Methods and reagents for the treatment of immunoinflammatory disorders
ITMI20050704A1 (it)	2005-10-22	Dispositivo semiconduttore e metodo di produzione dello stesso
DK1478438T3 (da)	2012-08-27	Fremgangsmåder og sammensætninger til behandling af astma
IS8497A (is)	2006-06-02	Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
EP1611120A4 (en)	2008-04-23	NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DK1589973T4 (da)	2013-04-08	Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1750713T3 (da)	2013-02-11	Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
NO20043505L (no)	2004-08-23	Rorelement, samt anordning og fremgangsmate for tilvirkning
NO20044012D0 (no)	2004-09-23	Fremgangsmate og et system